Summary & Overview
HCPCS J2278: Ziconotide Injection, 1 Microgram
HCPCS Level II code J2278 denotes the injection of ziconotide billed per 1 microgram, an intrathecal analgesic used for refractory chronic pain. This code matters nationally because ziconotide is a non-opioid option for severe, treatment-resistant pain delivered via intrathecal infusion systems, with implications for specialty pharmacy, facility billing, and payer medical policy. Coverage and reimbursement patterns for high-cost intrathecal medications influence access and site-of-service decisions across the continuum of care.
Key payers in this national overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of what the code represents, payer coverage considerations, typical sites of service, and the clinical context for ziconotide use. The publication also outlines common modifiers associated with complex drug administration billing and notes when input data are not available.
This analysis is intended to inform billing staff, revenue cycle leaders, and policy analysts about how HCPCS Level II code J2278 is used in clinical and billing workflows, highlight common documentation touchpoints for intrathecal drug administration, and summarize areas where payers commonly apply utilization management or prior authorization.
Billing Code Overview
HCPCS Level II code J2278 describes an injection of ziconotide, billed per 1 microgram. The service represents administration of an intrathecal analgesic agent used for severe chronic pain management when other therapies are inadequate or contraindicated.
Service type: Drug administration (intrathecal neuroaxial therapy)
Typical site of service: Hospital outpatient department, ambulatory surgical center, or other facility settings where intrathecal drug delivery and monitoring are provided.
Clinical & Coding Specifications
Clinical Context
A patient with chronic, refractory neuropathic pain or severe chronic pain syndromes refractory to systemic analgesics is referred for intrathecal ziconotide therapy. The patient is evaluated in a multidisciplinary pain clinic by a pain medicine specialist (often an anesthesiologist or physiatrist) and neurosurgery for pump candidacy. After informed consent and baseline neurologic and functional assessments, an intrathecal drug delivery system (IDDS) or trial intrathecal injection is planned. The service described by J2278 (injection, ziconotide, 1 microgram) is typically administered in an outpatient ambulatory surgery center or hospital outpatient department during a trial injection or for bolus dosing via an implanted intrathecal catheter/pump reservoir. Typical workflow: pre-procedure assessment and medication reconciliation; appropriate imaging review; sterile intrathecal access (via lumbar puncture for trial or reservoir access for pump dosing); administration of preservative-free ziconotide; short post-procedure observation for neurologic and psychiatric adverse effects; documentation of dosage in micrograms and lot/serial numbers for billing; and coordination for ongoing intrathecal therapy management and follow-up with pain clinic and device clinic staff.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier / default | Use when no other modifier applies and a single, standard service is billed |